Njira Lugogo, MD
Pulmonary Disease · Ann Arbor, MINPI 1649219734
Payments from drug & device makers
Across 1,879 payments — averaging $6874.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5.8M
- Teva Pharmaceuticals USA, Inc.$2.4M
- Janssen Research & Development, LLC$1.9M
- GSK$740K
- Genentech, Inc.$482K
- Regeneron$461K
- plus $1.1M from 15 others
Across 141 payments — averaging $501.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$33K
- Regeneron$26K
- Amgen$8K
- Teva Pharmaceuticals USA, Inc.$3K
- Sanofi US Services Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 224 | $5,811,888 |
| Teva Pharmaceuticals USA, Inc. | 82 | $2,374,433 |
| Janssen Research & Development, LLC | 42 | $1,915,580 |
| GSK | 241 | $739,877 |
| Genentech, Inc. | 41 | $481,619 |
| Regeneron | 1,014 | $460,607 |
| Sanofi US Services Inc. | 45 | $355,386 |
| Sanofi | 51 | $335,609 |
| Astrazeneca AB | 15 | $139,185 |
| Astrazeneca UK Limited | 52 | $138,999 |
| Novartis | 5 | $69,083 |
| Pfizer | 3 | $42,955 |
| Regeneron Healthcare Solutions, Inc. | 24 | $14,540 |
| Genentech USA, Inc. | 15 | $10,661 |
| Chiesi USA, Inc. | 7 | $9,128 |
| Sanofi-aventis U.S. LLC | 2 | $8,695 |
| Amgen | 11 | $5,593 |
| Incyte Corporation | 2 | $2,445 |
| AbbVie | 1 | $575 |
| Insmed, Inc. | 1 | $44 |
| Circassia Inc. | 1 | $41 |
How this compares
$12,916,943 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Ann Arbor
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Yvonne HuangAnn Arbor$1.1M
- Elizabeth BelloliAnn Arbor$806K
- Jamie ShethAnn Arbor$735K
- Wassim LabakiAnn Arbor$601K
- Shijing JiaAnn Arbor$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.